Strong Financial Performance#
Oppenheimer has reiterated a Perform rating on Intuitive Surgical (NASDAQ:ISRG) following the company's impressive first-quarter results. Intuitive Surgical reported a revenue of $2.77 billion, surpassing Oppenheimer's estimate of $2.62 billion and matching consensus expectations. The company's earnings per share (EPS) also exceeded expectations, coming in at $2.28 compared to Oppenheimer's estimate of $2.00 and a consensus of $1.97.
System Sales and Pricing#
The average selling price for Intuitive Surgical's systems rose to $1.7 million, driven by the sales mix of the da Vinci 5 single and dual-console models. The company placed 192 da Vinci 5 systems in the U.S. during the first quarter, which accounted for 85% of U.S. placements, although this was a decrease from 260 systems placed in the previous quarter. Internationally, 40 systems were placed.
Updated Guidance and Market Considerations#
Intuitive Surgical has updated its gross margin guidance to a range of 67.5% to 68.5%. This adjustment takes into account various macroeconomic factors such as oil prices, memory costs, and logistics expenses. However, the company expects to offset these impacts through cost reductions in its SP and Ion products.
Cautious Outlook from Oppenheimer#
Oppenheimer expressed a cautious outlook, citing several factors. The U.S. systems market is increasingly driven by replacements, and international markets are becoming essential for growth amid geopolitical tensions. The stock is currently valued at approximately 13 times forward price-to-sales and 43 times forward price-to-earnings. Additionally, the stock has declined 20% year-to-date and is trading near its 52-week low, indicating potential overvaluation concerns. Despite the strong financial results, the stock experienced a slight decline during regular trading but rebounded in aftermarket trading, reflecting the complex nature of investor reactions.